We have previously demonstrated that SHR-5 and one of its bioactive components, salidroside, inhibit the growth of bladder cancer cell lines with minimal effect on the growth of non-malignant bladder urothelial cells via the inhibition of the mTOR pathway and induction of autophagy [10]. This evidence concerns the gene MTOR and urinary bladder carcinoma.